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HER2 is the only molecular marker in breast cancer to 
make its way into clinical practice. Th  is protein kinase 
receptor has become a thera  peutical target since the 
development by Genen  tech (South San Francisco, CA, 
USA) of anti-HER2 monoclonal antibodies. But do 
HER2-positive breast cancers form a homogeneous 
group of tumors? Th   is question is addressed by Staaf and 
colleagues in this issue of Breast Cancer Research [1].
Ampliﬁ  cation and overexpression of the HER2 gene in 
about 15% of breast cancers were originally discovered in 
1987 [2,3], in the early days of molecular oncology. Since 
that time, technologies have changed, the human genome 
has been sequenced, and DNA arrays allow investigators 
to address genetic changes on a genome-wide scale. Our 
views of breast cancer and of the sequence of oncogenic 
changes that govern its emergence have changed 
considerably as well.
For HER2-positive breast cancers, the introduction of 
trastuzumab has been a radical change, improving the 
outcome of these patients substantially. Th  is  success  has 
contributed to the deﬁ  nition of a HER2-positive breast 
cancer subclass. However, a number of patients show 
either primary or acquired resistance to this therapy. Th  is 
clinical reality motivated the group of Ake Borg [1] at the 
University of Lund, Sweden, to address the question of 
the biological homogeneity of HER2-positive tumors. To 
do this, they collaborated with colleagues from the 
University of Iceland in the collection of a large (200) 
series of primary HER2-positive breast cancers, which 
they characterized by CGH (comparative genomic 
hybridi  zation) using tiling-path BAC (bacterial artiﬁ  cial 
chromosome) array. Th  ese data were related to an 
external dataset comprising CNA (copy number altera-
tion) proﬁ   les from 554 HER2-negative breast tumors. 
Th  e  principal  ﬁ  nding of this work is that HER2-positive 
breast cancers present a large diversity of anomalies 
aﬀ  ecting most of the genome. Th  ey show, apart from 
HER2 ampliﬁ  cation, high-level ampliﬁ  cation at multiple 
sites and a number of these ampliﬁ  cations correspond to 
known oncogenes (FGFR1, MYC, CCND1, and ZNF217). 
Some apparently distinguishing features of HER2-positive 
breast tumors are the so-called ﬁ  restorm  patterns. 
Firestorms correspond to multiple focal ampliﬁ  cations of 
neighboring loci. Th  ese occurred on a number of 
chromosomal arms but principally at 17q. Such patterns 
concentrated on the chromosomal arm carrying the 
HER2 locus raise interesting questions about the 
mechanism at work. Th  e  ﬁ  rst idea that comes to mind is 
that it may correspond to a cooperative mechanism 
resulting in the selection of secondary mutations. As is 
often the case, the reality is more complex since only a 
few of these ﬁ  restorm amplicons at 17q were recurrent. 
Th   e second important ﬁ  nding concerns ampliﬁ  cation of 
the HER2 locus, which can be split into two subsets: (a) 
narrow amplicons (86 kb in its smallest form) that 
centered around HER2 and that comprise 6 to 10 genes, 
of which 4 showed recurrent overexpression, and (b) a 
large amplicon (1.1 Mb) starting centromeric to HER2
and extending telomeric to the TOP2A gene. Th  e  abrupt 
break downstream of TOP2A is a clear indication of a 
coselection. Th   is work shows that these two ampliﬁ  cation 
patterns point to diﬀ   erent breast cancer subsets. Th  e 
small amplicon is found in estrogen receptor (ER)-
negative tumors, whereas HER2/TOP2A coampliﬁ  cation 
is correlated with ER-positive tumors and a better 
survival. Th   ere are other signs that HER2-positive tumors 
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ER+ presented diﬀ   erent patterns of anomalies; in 
particular, loss at 5q was limited to ER− and ampliﬁ  cation 
at 11q13 was limited to ER+. HER2+/ER− showed higher 
ploidy indices and proﬁ  les that were more rearranged 
than those of their ER+ counterparts.
Th  is work parallels and complements an earlier study 
by the same group [4]; that study was based on expression 
proﬁ  ling and aimed at determining a molecular predictor 
of bad outcome in HER2-positive tumors. A total of 58 
HER2-positive breast cancers were analyzed. By unsuper-
vised analysis, three clusters of tumors, one of which 
presented a substantially worse outcome, were deline-
ated. A 158-gene prognostic predictor speciﬁ  c to HER2-
positive breast cancer was proposed.
Altogether, these data bring clear evidence that HER2-
positive breast tumors do not form a homogeneous 
biological entity. Th   is was already apparent in molecular 
subtypes deﬁ   ned by unsupervised expression proﬁ  ling 
classiﬁ   cation. Four to ﬁ   ve molecular subtypes, one of 
which was the ERBB2 subtype, were described [5]. It was 
soon apparent that this ERBB2 subtype was not 
exclusively composed of HER2-ampliﬁ  ed breast tumors 
and, conversely, that HER2-positive tumors clustered in 
other molecular subgroups. Th  is was very clearly con-
ﬁ  rmed by Weigelt and colleagues [6] in a recent study 
(2010) comparing the relative eﬃ   ciency of two single-
sample predictors (SSPs). Th  ere are repeated calls for a 
reﬁ  ned molecular classiﬁ  cation, but there is a reasonable 
likelihood that it would not delineate a subgroup 
corresponding to HER2-positive cancers.
If HER2-positive tumors do not correspond to a 
biological subclass of breast cancer, they deﬁ  ne a clinical 
subset of patients. Th  is determines its importance and 
the huge eﬀ  orts that are deployed to better characterize 
them. It must be mentioned that in the framework of the 
International Cancer Genome Consortium (ICGC), 
which aims at sequencing the genome of 500 tumors of at 
least 50 cancer types, France has decided to take HER2-
positive breast cancer as a target. Th  e genomic hetero-
geneity revealed by the work of Staaf and colleagues [1] 
calls for further work in order to determine the lines 
along which we will delineate the diﬀ  erent subsets of 
HER2-positive breast cancers. It will be interesting, in 
particular, to see whether it is possible to outline a 
coherent scheme of co-occurring ampliﬁ  cations. If such a 
scheme exists, it may be a good basis on which to deﬁ  ne 
complementary therapies by targeting genes coampliﬁ  ed 
with HER2. Th   ere are great expectations that the ICGC 
program will bring answers to these questions.
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